The effect of a low dose hydrogen-oxygen mixture inhalation in midlife/older adults with hypertension: A randomized, placebo-controlled trial.
Boyan Liu, Xue Jiang, Yunbo Xie, Xiubin Jia, Jiashuo Zhang, Yazhuo Xue, Shucun Qin · Frontiers in pharmacology · 2022
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 60 participants with hypertension aged 50-70 years, when stratified by age (aged 50-59 years versus aged 60-70 years), participants in the older H₂-O₂ group showed a larger reduction in right arm SBP compared with that in the younger group (p < 0.05). These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence blood-pressure regulation.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in 60 participants with hypertension aged 50-70 years. When stratified by age (aged 50-59 years versus aged 60-70 years), participants in the older H₂-O₂ group showed a larger reduction in right arm SBP compared with that in the younger group (p < 0.05).
What the Researchers Studied
The researchers studied 60 participants with hypertension aged 50-70 years. The study used a randomized, placebo-controlled human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
33% inhaled H₂ concentration; reported treatment duration: 2 weeks. When stratified by age (aged 50-59 years versus aged 60-70 years), participants in the older H₂-O₂ group showed a larger reduction in right arm SBP compared with that in the younger group (p < 0.05).
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence blood-pressure regulation and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, placebo-controlled human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 60 participants with hypertension aged 50-70 years. The reported sample size was 60. The study used a randomized, placebo-controlled human clinical trial. The hydrogen delivery method was inhaled hydrogen gas. The reported hydrogen concentration was 33% inhaled H₂ concentration. The reported treatment duration was 2 weeks.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.